Health-Related Quality of Life in Children with X-Linked Hypophosphatemia Treated with Burosumab: Real-World Data from a German-Swiss Study
Rattachement africain : de, ch. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Burosumab is effective in improving rickets in children with X-linked hypophosphatemia (XLH). Predictors of health-related quality of life (HRQoL) in pediatric XLH patients treated with burosumab are unknown. In this cross-sectional analysis of a prospective binational observational study, we investigated HRQoL in 64 pediatric XLH patients (36 female) on burosumab treatment, using the KIDSCREEN-52 questionnaire and qualitative interviews. Associations between HRQoL and clinical findings were analysed using multiple regression and receiver operating characteristics (ROC) curve analyses. Median age at investigation and duration of burosumab treatment were 13.1 (IQR 10.4; 14.8) and 2.8 (IQR 1.4; 3.8) years, respectively; 54.7% of patients received secondary burosumab treatment following prior active vitamin D and phosphate. Overall, HRQoL scores were comparable to national reference values. Caregivers rated Physical Well-Being, Moods & Emotions, and Bullying lower than the patients themselves. Burosumab dose was significantly associated with Physical Well-Being, Psychological Well-Being, and Self-Perception in self-report, and with total T-values and Physical Well-Being in proxy questionnaires. The duration of prior treatment with active vitamin D and phosphate was significantly associated with the dimension of Autonomy in self-report and proxy reports. A burosumab dosage above 0.6 mg/kg was associated with a good Physical Well-Being (above the mean of the general population) with a sensitivity and specificity of 75% and 70% in self-report, and 67% and 70% in proxy questionnaires, respectively. In this real-world study, HRQoL in burosumab-treated children with XLH was comparable to that of the general population and associated with burosumab dosage.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Health-Related Quality of Life in Children with X-Linked Hypophosphatemia Treated with Burosumab: Real-World Data from a German-Swiss Study
- Date Crossref
- 16/09/2026
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Medizinische Hochschule Hannover pays non établi dans la noticeUniversité ou école supérieure
-
Catholic University of Applied Sciences of North Rhine – Westphalia pays non établi dans la noticeUniversité ou école supérieure
-
University Hospital Cologne pays non établi dans la noticeÉtablissement de santé
-
University Children's Hospital Zurich Pediatric Nephrology pays non établi dans la noticeÉtablissement de santé
-
University Hospital Münster pays non établi dans la noticeÉtablissement de santé
-
Asklepios pays non établi dans la noticeÉtablissement de santé
-
University of Lübeck Department of Pediatric and Adolescent Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Universitätsmedizin Greifswald pays non établi dans la noticeÉtablissement de santé
-
Johannes Gutenberg University Mainz pays non établi dans la noticeUniversité ou école supérieure
-
University Medical Center of the Johannes Gutenberg University Mainz pays non établi dans la noticeÉtablissement de santé
-
Universitätsmedizin Göttingen pays non établi dans la noticeÉtablissement de santé
-
University Children's Hospital Tübingen pays non établi dans la noticeÉtablissement de santé
Medizinische Hochschule Hannover, Catholic University of Applied Sciences of North Rhine – Westphalia et University Hospital Cologne, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.